Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection

American Journal of Gastroenterology

Volumn 103, Issue 8, 2008, Pages 1933-1940

  Huang, Jee Fu ^a,b,c   Yu, Ming Lung ^c,d   Dai, Chia Yen ^b,c,d   Hsieh, Ming Yen ^c   Hwang, Shang Jyh ^c,d   Hsiao, Pi Jung ^c   Lee, Li Po ^c   Lin, Zu Yau ^c,d   Chen, Shinn Chern ^c,d   Hsieh, Ming Yuh ^c,d   Wang, Liang Yen ^c,d   Shin, Shyi Jang ^c,d   Chang, Wen Yu ^c   Chuang, Wan Long ^c,d  

^a KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PREVALENCE; VIRAL LOAD;

EID: 49349114385     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01996.x     Document Type: Article

References (26)

1. Mazzaro C, Panarello G, Tesio F, et al. Hepatitis C virus risk: A hepatitis C virus related syndrome. J Intern Med 2000 247 : 535 45.
2. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepatitis 1997 4 : 9 28.
3. Huang JF, Chuang WL, Dai CY, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: Another chain of link? J Intern Med 2006 260 : 255 62.
4. Huang JF, Chuang WL, Dai CY, et al. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C Patients with interferon-alpha and ribavirin combination therapy. J Viral Hepatitis 2006 13 : 396 401.
5. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999 29 : 328 33.
6. Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in non-cirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000 75 : 355 9.
7. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000 133 : 592 9.
8. Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: An epidemiological link with virological implication. Am J Gastroenterol 2007 102 : 1237 43.
9. Saltiel AR, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 2001 414 : 799 806.
10. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992 15 : 815 9.
11. American Diabetes Association. Standards of medical care in diabetes, 2006. Diabetes Care 2006 29 : S4 42.
12. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham study. Diabetes Care 1979 2 : 120 6.
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005 28 : S37 42.
14. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993 74 : 2385 90.
15. Hung WW, Chang CJ, Lee YJ, et al. Metabolic risk factors in southern Taiwanese with impaired fasting glucose 100-109 mg/dL. Metabolism 2007 56 : 528 32.
16. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002 359 : 2072 7.
17. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired fasting glucose: A randomized controlled trail. Lancet 2006 368 : 1096 105.
18. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001 344 : 1343 50.
19. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003 26 : S5 20.
21. The DECODE-study group on behalf of the European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiologic data from 20 European studies. Diabetologia 1999 42 : 647 54.
22. Lecube A, Hernandez C, Genesca J, et al. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care 2004 27 : 1171 5.
23. Lecube A, Hernandez C, Genesca J, et al. Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis. Diabetes Care 2006 29 : 1140 9.
24. Zein CO, Levy C, Basu A, et al. Chronic hepatitis C and type II diabetes mellitus: A prospective cross-sectional study. Am J Gastroenterol 2005 100 : 48 55.
25. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126 : 840 8.
26. Chuang WL, Yu ML, Dai CY, et al. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006 49 : 99 106.